Key result
Among patients with non-valvular atrial fibrillation taking vitamin K antagonists, 30.2% were classified as having a high risk of major bleeding based on a HAS-BLED score of 3 or greater.
Cohort (n=63)
No
Approximately 30% of patients with non-valvular AF on vitamin K antagonists have a high risk of major bleeding, emphasizing the need to manage modifiable risk factors such as labile INR and concomitant drug use.
Supports vigilance for modifiable bleeding risks in VKA-treated AF; leaves open prospective evaluation of targeted interventions.
The use of risk scores for the assessment of major bleeding and stroke in patients with atrial fibrillation (AF) helps evaluate the risks and benefits of oral anticoagulation therapy. The aim of this study was to describe the percentage of patients receiving anticoagulants for non-valvular AF with a high risk of major bleeding based on the HAS-BLED score, as well as identify potential modifiable risk factors of bleeding and compare the risk of major bleeding with the risk of stroke.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2015) conducted a cohort in Non-valvular atrial fibrillation (n=63). Vitamin K antagonists was evaluated on Percentage of patients with a high risk of major bleeding based on a HAS-BLED score ≥ 3. Among patients with non-valvular atrial fibrillation taking vitamin K antagonists, 30.2% were classified as having a high risk of major bleeding based on a HAS-BLED score of 3 or greater.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: